1. SUBCUTANEOUS IMMUNOTHERAPY

TABLE G1. STUDY CHARACTERISTICS SCIT- PEDIATRICS (MS Word, 49K)

TABLE G2. PATIENT CHARACTERISTICS SCIT- PEDIATRICS (MS Word, 49K)

TABLE G3. INTERVENTION CHARACTERISTICS -SCIT- PEDIATRICS (MS Word, 52K)

TABLE G4. RISK OF BIAS-SCIT- PEDIATRICS (MS Word, 48K)

TABLE G5. ASTHMA SYMPTOM SCORES- SCIT-PEDIATRICS (MS Word, 47K)

TABLE G6. ASTHMA MEDICATION SCORES- SCIT- PEDIATRICS (MS Word, 46K)

TABLE G7. ASTHMA COMBINED SYMPTOM AND MEDICATION SCORES- SCIT- PEDIATRICS (MS Word, 45K)

TABLE G8. SCIT – ASTHMA STUDIES REPORTING COMBINED ASTHMA AND RHINOCONJUNCTIVITIS MEDICATION SCORES – SCIT- PEDIATRICS (MS Word, 45K)

TABLE G9. ASTHMA PFT RESULTS- SCIT-PEDIATRICS (MS Word, 45K)

TABLE G10. SCIT-CHALLENGES SCORES- SCIT-PEDIATRICS (MS Word, 47K)

TABLE G11. RHINITIS AND RHINOCONJUNCTIVITIS SYMPTOM SCORES- SCIT-PEDIATRICS (MS Word, 46K)

TABLE G12. OCULAR SYMPTOM SCORES- SCIT-PEDIATRICS (MS Word, 45K)

TABLE G13. RHINITIS COMBINED SYMPTOMS AND MEDICATION SCORES-SCIT- PEDIATRICS (MS Word, 45K)

TABLE G14. ASTHMA QOL -SCIT- PEDIATRICS (MS Word, 45K)

TABLE G15. RHINITIS/RHINOCONJUNCTIVITIS QOL - SCIT- PEDIATRICS (MS Word, 46K)

TABLE G16. RHINITIS – PREVENTION OF ASTHMA -SCIT- PEDIATRICS (MS Word, 45K)

TABLE G17. SAFETY – SCIT - PEDIATRICS (MS Word, 51K)

2. SUBLINGUAL IMMUNOTHERAPY

TABLE G18. STUDY CHARACTERISTICS SLIT – PEDIATRICS (MS Word, 51K)

TABLE G19. PATIENT CHARACTERISTICS SLIT – PEDIATRICS (MS Word, 53K)

TABLE G20. INTERVENTION CHARACTERISTICS –SLIT – PEDIATRICS (MS Word, 52K)

TABLE G21. QUALITY ASSESSMENT – SLIT – PEDIATRICS (MS Word, 49K)

TABLE G22. ASTHMA AND ASTHMA COMBINED SYMPTOM SCORES –SLIT– PEDIATRICS (MS Word, 50K)

TABLE G23. RHINITIS AND RHINOCONJUNCTIVITIS SYMPTOM SCORES –SLIT– PEDIATRICS (MS Word, 48K)

TABLE G24. CONJUNCTIVITIS SYMPTOM SCORES –SLIT– PEDIATRICS (MS Word, 47K)

TABLE G25. MEDICATION SCORES–SLIT– PEDIATRICS (MS Word, 51K)

TABLE G26. COMBINED SYMPTOM AND MEDICATION SCORES –SLIT– PEDIATRICS (MS Word, 45K)

TABLE G27. QUALITY OF LIFE –SLIT– PEDIATRICS (MS Word, 45K)

TABLE G28. CHALLENGES SCORES –SLIT– PEDIATRICS (MS Word, 51K)

TABLE G29. TOTAL SECONDARY OUTCOMES –SLIT– PEDIATRICS (MS Word, 48K)

TABLE G30. BIOMARKERS –SLIT– PEDIATRICS (MS Word, 51K)

TABLE G31. SAFETY–SLIT– PEDIATRICS (MS Word, 60K)

3. SUBCUTANEOUS vs SUBLINGUAL IMMUNOTHERAPY

TABLE G32. STUDY CHARACTERISTICS - SCIT vs SLIT - PEDIATRICS (MS Word, 45K)

TABLE G33. PATIENT CHARACTERISTICS- SCIT vs SLIT - PEDIATRICS (MS Word, 46K)

TABLE G34. INTERVENTION CHARACTERISTICS- SCIT vs SLIT - PEDIATRICS (MS Word, 46K)

TABLE G35. QUALITY ASSESSMENT- SCIT vs SLIT - PEDIATRICS (MS Word, 45K)

TABLE G36. ASTHMA AND ASTHMA COMBINED SCORES- SCIT vs SLIT - PEDIATRICS (MS Word, 45K)

TABLE G37. RHINITIS AND RHINOCONJUNCTIVITIS SYMPTOM SCORES SCIT vs SLIT -PEDIATRICS (MS Word, 45K)

TABLE G38. OTHER CLINICAL SCORES, SCIT vs SLIT- PEDIATRICS (MS Word, 46K)

TABLE G39. MEDICATION SCORES SCIT vs SLIT - PEDIATRICS (MS Word, 46K)

TABLE G40. ALLERGY CHALLENGES AND FUNCTIONAL OUTCOMES: SCIT vs SLIT - PEDIATRICS (MS Word, 46K)

TABLE G41. BIOMARKERS – SCIT vs SLIT – PEDIATRICS - IgE (MS Word, 46K)

TABLE G42. SAFETY - SCIT vs SLIT - PEDIATRICS (MS Word, 46K)

REFERENCES PEDIATRICS APPENDIX

1.

Hill DJ, Hosking CS, Shelton MJ, Turner MW. Failure of hyposensitisation in treatment of children with grass-pollen asthma. Br Med J (Clin Res Ed). 1982;284(6312):306–9. [PMC free article: PMC1495893] [PubMed: 6800440]

2.

Altintas D, Akmanlar N, Guneser S, et al. Comparison between the use of adsorbed and aqueous immunotherapy material in Dermatophagoides pteronyssinus sensitive asthmatic children. Allergol Immunopathol (Madr). 1999;27(6):309–17. [PubMed: 10611556]

3.

Pifferi M, Baldini G, Marrazzini G, et al. Benefits of immunotherapy with a standardized Dermatophagoides pteronyssinus extract in asthmatic children: a three-year prospective study. Allergy. 2002;57(9):785–90. [PubMed: 12169173]

4.

Van Bever HP, Stevens WJ. Evolution of the late asthmatic reaction during immunotherapy and after stopping immunotherapy. J Allergy Clin Immunol. 1990;86(2):141–6. [PubMed: 2384645]

5.

Schubert R, Eickmeier O, Garn H, et al. Safety and immunogenicity of a cluster specific immunotherapy in children with bronchial asthma and mite allergy. Int Arch Allergy Immunol. 2009;148(3):251–60. [PubMed: 18849616]

6.

Valovirta E, Viander M, Koivikko A, Vanto T, Ingeman L. Immunotherapy in allergy to dog. Immunologic and clinical findings of a double-blind study. Ann Allergy. 1986;57(3):173–9. [PubMed: 3752618]

7.

Valovirta E, Koivikko A, Vanto T, Viander M, Ingeman L. Immunotherapy in allergy to dog: a double-blind clinical study. Ann Allergy. 1984;53(1):85–8. [PubMed: 6742528]

8.

Adkinson NF Jr, Eggleston PA, Eney D, et al. A controlled trial of immunotherapy for asthma in allergic children. N Engl J Med. 1997;336(5):324–31. [PubMed: 9011784]

9.

Limb SL, Brown KC, Wood RA, Eggleston PA, Hamilton RG, Adkinson NF Jr. Long-term immunologic effects of broad-spectrum aeroallergen immunotherapy. Int Arch Allergy Immunol. 2006;140(3):245–51. [PubMed: 16691031]

10.

Moller C, Dreborg S, Ferdousi HA, et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol. 2002;109(2):251–6. [PubMed: 11842293]

11.

Niggemann B, Jacobsen L, Dreborg S, et al. Five-year follow-up on the PAT study: specific immunotherapy and long-term prevention of asthma in children. Allergy. 2006;61(7):855–9. [PubMed: 16792584]

12.

Jacobsen L, Niggemann B, Dreborg S, et al. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy. 2007;62(8):943–8. [PubMed: 17620073]

13.

Akmanlar N, Altintas DU, Guneser KS, Yilmaz M, Bingol G. Comparison of conventional and rush immunotherapy with der PI in childhood respiratory allergy. Allergol Immunopathol (Madr). 2000;28(4):213–8. [PubMed: 11022267]

14.

Hedlin G, Wille S, Browaldh L, et al. Immunotherapy in children with allergic asthma: effect on bronchial hyperreactivity and pharmacotherapy. J Allergy Clin Immunol. 1999;103(4):609–14. [PubMed: 10200009]

15.

Cantani A, Arcese G, Lucenti P, Gagliesi D, Bartolucci M. A three-year prospective study of specific immunotherapy to inhalant allergens: evidence of safety and efficacy in 300 children with allergic asthma. J Investig Allergol Clin Immunol. 1997;7(2):90–7. [PubMed: 9161933]

16.

Dreborg S, Agrell B, Foucard T, Kjellman NI, Koivikko A, Nilsson S. A double-blind, multicenter immunotherapy trial in children, using a purified and standardized Cladosporium herbarum preparation. I. Clinical results. Allergy. 1986;41(2):131–40. [PubMed: 3518526]

17.

Kuna P, Kaczmarek J, Kupczyk M. Efficacy and safety of immunotherapy for allergies to Alternaria alternata in children. The Journal of allergy and clinical immunology. 2011:502–508. e1–6. [PubMed: 21281874]

18.

Pajno GB, Morabito L, Barberio G, Parmiani S. Clinical and immunologic effects of long-term sublingual immunotherapy in asthmatic children sensitized to mites: a double-blind, placebo-controlled study. Allergy. 2000;55(9):842–9. [PubMed: 11003448]

19.

Lue KH, Lin YH, Sun HL, Lu KH, Hsieh JC, Chou MC. Clinical and immunologic effects of sublingual immunotherapy in asthmatic children sensitized to mites: a double-blind, randomized, placebo-controlled study. Pediatr Allergy Immunol. 2006;17(6):408–15. [PubMed: 16925685]

20.

Niu CK, Chen WY, Huang JL, Lue KH, Wang JY. Efficacy of sublingual immunotherapy with high-dose mite extracts in asthma: a multi-center, double-blind, randomized, and placebo-controlled study in Taiwan. Respir Med. 2006;100(8):1374–83. [PubMed: 16403616]

21.

de Bot CM, Moed H, Berger MY, et al. Sublingual immunotherapy not effective in house dust mite-allergic children in primary care. Pediatr Allergy Immunol. 2011 [PubMed: 22017365]

22.

Tseng SH, Fu LS, Nong BR, Weng JD, Shyur SD. Changes in serum specific IgG4 and IgG4/IgE ratio in mite-sensitized Taiwanese children with allergic rhinitis receiving short-term sublingual-swallow immunotherapy: a multicenter, randomized, placebo-controlled trial. Asian Pac J Allergy Immunol. 2008;26(2–3):105–12. [PubMed: 19054928]

23.

La Rosa M, Ranno C, Andre C, Carat F, Tosca MA, Canonica GW. Double-blind placebo-controlled evaluation of sublingual-swallow immunotherapy with standardized Parietaria judaica extract in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol. 1999;104(2 Pt 1):425–32. [PubMed: 10452766]

24.

Leonardi S, Spicuzza L, La Rosa M. High-dose sublingual immunotherapy in children at 8-year follow-up. Ann Allergy Asthma Immunol. 2009;102(3):259–60. [PubMed: 19354077]

25.

Novembre E, Galli E, Landi F, et al. Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2004;114(4):851–7. [PubMed: 15480326]

26.

Roder E, Berger MY, Hop WC, Bernsen RM, de Groot H, Gerth van Wijk R. Sublingual immunotherapy with grass pollen is not effective in symptomatic youngsters in primary care. J Allergy Clin Immunol. 2007;119(4):892–8. [PubMed: 17321581]

27.

Stelmach I, Kaluzinska-Parzyszek I, Jerzynska J, Stelmach P, Stelmach W, Majak P. Comparative effect of pre-coseasonal and continuous grass sublingual immunotherapy in children. Allergy: European Journal of Allergy and Clinical Immunology. 2011 [PubMed: 22142341]

28.

Marogna M, Tomassetti D, Bernasconi A, et al. Preventive effects of sublingual immunotherapy in childhood: an open randomized controlled study. Ann Allergy Asthma Immunol. 2008;101(2):206–11. [PubMed: 18727478]

29.

Hirsch T, Sahn M, Leupold W. Double-blind placebo-controlled study of sublingual immunotherapy with house dust mite extract (D.pt.) in children. Pediatr Allergy Immunol. 1997;8(1):21–7. [PubMed: 9260215]

30.

Bahceciler NN, Isik U, Barlan IB, Basaran MM. Efficacy of sublingual immunotherapy in children with asthma and rhinitis: a double-blind, placebo-controlled study. Pediatr Pulmonol. 2001;32(1):49–55. [PubMed: 11416876]

31.

Tari MG, Mancino M, Monti G. Efficacy of sublingual immunotherapy in patients with rhinitis and asthma due to house dust mite. A double-blind study. Allergol Immunopathol (Madr). 1990;18(5):277–84. [PubMed: 2097894]

32.

Pajno GB, Vita D, Feliciotto R, Neri M, Barberio G. Impact of sublingual immunotherapy on seasonal asthma of allergic children to parietaria pollen treated with inhaled fluticasone propionate. Journal of Allergy, Asthma and Immunolgy. [abstract] [PubMed: 14656349]

33.

Pajno GB, Passalacqua G, Vita D, Caminiti L, Parmiani S, Barberio G. Sublingual immunotherapy abrogates seasonal bronchial hyperresponsiveness in children with Parietaria-induced respiratory allergy: a randomized controlled trial. Allergy. 2004;59(8):883–7. [PubMed: 15230823]

34.

Vourdas D, Syrigou E, Potamianou P, et al. Double-blind, placebo-controlled evaluation of sublingual immunotherapy with standardized olive pollen extract in pediatric patients with allergic rhinoconjunctivitis and mild asthma due to olive pollen sensitization. Allergy. 1998;53(7):662–72. [PubMed: 9700035]

35.

Pajno GB, Caminiti L, Crisafulli G, et al. Direct comparison between continuous and coseasonal regimen for sublingual immunotherapy in children with grass allergy: A randomized controlled study. Pediatric Allergy and Immunology. 2011;22(8):803–807. [PubMed: 21929600]

36.

Valovirta E, Jacobsen L, Ljorring C, Koivikko A, Savolainen J. Clinical efficacy and safety of sublingual immunotherapy with tree pollen extract in children. Allergy. 2006;61(10):1177–83. [PubMed: 16942565]

37.

Savolainen J, Jacobsen L, Valovirta E. Sublingual immunotherapy in children modulates allergen-induced in vitro expression of cytokine mRNA in PBMC. Allergy. 2006;61(10):1184–90. [PubMed: 16942566]

38.

Ippoliti F, De Santis W, Volterrani A, et al. Immunomodulation during sublingual therapy in allergic children. Pediatr Allergy Immunol. 2003;14(3):216–21. [PubMed: 12787302]

39.

Eifan A, Akkoc T, Yildiz A, et al. Clinical efficacy and immunological mechanisms of sublingual and subcutaneous specific immunotherapy in asthmatic/rhinitis children sensitised to house-dust-mite: an open randomised controlled study. Allergy. 2010 [PubMed: 20100188]

40.

Yukselen A, Kendirli SG, Yilmaz M, Altintas DU, Karakoc GB. Effect of One-Year Subcutaneous and Sublingual Immunotherapy on Clinical and Laboratory Parameters in Children with Rhinitis and Asthma: A Randomized, Placebo-Controlled, Double-Blind, Double-Dummy Study. International Archives of Allergy and Immunology. 2011;157(3):288–298. [PubMed: 22041501]

41.

Keles S, Karakoc-Aydiner E, Ozen A, et al. A novel approach in allergen-specific immunotherapy: combination of sublingual and subcutaneous routes. J Allergy Clin Immunol. 2011;128(4):808–815. e7. [PubMed: 21641635]